Correction: Time-dependent diffusion MRI for noninvasive molecular subtype differentiation and biological correlation in breast cancer: emphasizing the emerging three-tier HER2 classification - Report - MDSpire

Correction: Time-dependent diffusion MRI for noninvasive molecular subtype differentiation and biological correlation in breast cancer: emphasizing the emerging three-tier HER2 classification

  • By

  • Mingzhe Xu

  • Kuiyuan Liu

  • Shouning Zhang

  • Haotian Li

  • Renzhi Zhang

  • Chunmiao Xu

  • Junhui Yuan

  • Yue Wu

  • Dan Wu

  • Xuejun Chen

  • Jinrong Qu

  • June 9, 2026

  • 0 min

Share

Correction: Time-Dependent Diffusion MRI for Noninvasive Differentiation of Molecular Subtypes

Overview

This correction addresses the omission of funding information in the original article regarding time-dependent diffusion MRI in breast cancer. The updated funding statement now includes support from the Henan Province Central Plains Talent Program.

Background

Accurate classification of breast cancer subtypes is critical for guiding treatment decisions. The three-tier HER2 classification system represents an important advancement in understanding HER2 status.

Data Highlights

No numerical or trial data presented in the correction.

Key Findings

['The funding statement for the original article has been updated to include the Henan Province Central Plains Talent Program.', 'Financial support was also received from the National High Level Hospital Clinical Research Funding and the National Cancer Cencer Climbing Fund.', 'The correction highlights the importance of accurate reporting in clinical research publications.', 'Time-dependent diffusion MRI is a technique for differentiating molecular subtypes in breast cancer.', 'The three-tier HER2 classification is relevant for treatment eligibility.']

Clinical Implications

Understanding the three-tier HER2 classification can aid in making informed treatment decisions for breast cancer patients.

Conclusion

The correction serves to update the funding information in the original research publication.

Related Resources & Content

  1. Xu M, Liu K, Zhang S, et al., Frontiers in Oncology, 2026 -- Correction: Time-Dependent Diffusion MRI for Noninvasive Differentiation of Molecular Subtypes and Biological Associations in Breast Cancer
  2. The ASCO Post — Genomic Researchers Identify Weak Points in Breast Cancer Cells
  3. European Radiology — The Role of Diffusion-Weighted Imaging Combined with Contrast-Enhanced MRI in Assessing Complete Response in HER2-Positive Breast Cancer
  4. European Radiology — Establishment of a breast apparent diffusion coefficient classification system (ADC-B) based on data from a comprehensive multicenter MRI study
  5. European Radiology — A Deep Learning Approach for Classifying Grade 2 Nottingham Histologic Breast Tumors Using Dynamic Contrast-Enhanced MRI
  6. International Expert Consensus Recommendations for HER2 Reporting in Breast Cancer: Focus on HER2-Low and Ultralow Categories - ScienceDirect
  7. Reporting Template for Reporting Results of Biomarker Testing
  8. US Food and Drug Administration Approval Summary: Trastuzumab Deruxtecan for the Treatment of Adult Patients With Hormone Receptor–Positive, Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2–Low or Human Epidermal Growth Factor Receptor 2–Ultralow Breast Cancer | Journal of Clinical Oncology
  9. Table 2, Summary of Previous and Updated Classification Guidelines for HER2 Status in mBC - Trastuzumab Deruxtecan (Enhertu) - NCBI Bookshelf
  10. Trastuzumab deruxtecan in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of disease - PubMed
  11. Exploratory biomarker analysis of trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in HER2-low/ultralow, hormone receptor–positive (HR+) metastatic breast cancer (mBC) in DESTINY-Breast06 (DB-06). | Journal of Clinical Oncology
  12. Analytical and clinical validation of PATHWAY HER2 (4B5) assay for assessment of HER2-low/HER2-ultralow status and eligibility for trastuzumab deruxtecan in DESTINY-Breast06 - ScienceDirect
  13. Preview
  14. Time to Consider Diffusion Time: Exploring the Potential of Time-Dependent Diffusion MRI in Breast Cancer Imaging | Radiology: Imaging Cancer
  15. TYPE Original Research

Original Source(s)

Correction: Time-dependent diffusion MRI for noninvasive molecular subtype differentiation and biological correlation in breast cancer: emphasizing the emerging three-tier HER2 classification

  • by Mingzhe Xu, Kuiyuan Liu, Shouning Zhang, Haotian Li, Renzhi Zhang, Chunmiao Xu, Junhui Yuan, Yue Wu, Dan Wu, Xuejun Chen, Jinrong Qu

  • June 9, 2026

Related Content

An exploratory integrative analysis of plasma transcriptomic and proteomic predictors of response to total neoadjuvant therapy in locally advanced rectal cancer

Tislelizumab combined with gemcitabine as first-line treatment in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma: a single center, single-arm phase 2 trial

The gastrin-releasing peptide receptor in oncology: a comprehensive review of recent advances in targeted radionuclide theranostics